What is the difference between Class I, IIa, IIb, and III?

In short: EU MDR sorts devices into four risk classes. Class I (lowest risk) can mostly be self-certified — except sterile, measuring, or reusable-surgical sub-classes, which need Notified Body involvement; Class IIa, IIb, and III require a Notified Body, with scrutiny, cost, and clinical-evidence expectations rising by class. Your class is set by the 22 rules in MDR Annex VIII, based on intended purpose and risk.

The four classes, in practical terms

Class I covers the lowest-risk devices — think basic administrative or storage software, or simple non-invasive tools — and can generally be placed on the market with a self-declared technical file and no third-party review. The exception: Class I devices that are sterile, have a measuring function, or are reusable surgical instruments still need Notified Body involvement for that specific aspect. Class IIa is where most software with genuine clinical decision-support functionality lands under Rule 11: a Notified Body reviews your technical documentation and quality management system before you can CE mark. Class IIb applies where a wrong output could cause serious deterioration of health or require surgical intervention — more scrutiny, more clinical-evidence depth. Class III is reserved for the highest-risk devices, where an error could plausibly cause death or irreversible harm; expect the most demanding review and, often, a formal clinical investigation rather than reliance on equivalence or literature alone.

Why the class you land in changes almost everything

Classification isn't a paperwork step you sort out later — it's the fork that determines the shape of your entire evidence programme: how deep your clinical evaluation needs to be, whether you need a clinical investigation, and which parts of your quality system a Notified Body will actually inspect. Class I self-certifiers move fastest; Class IIa–III devices commonly take 12–18 months and a six-figure investment to reach CE marking, driven mainly by the QMS build, clinical evaluation, and Notified Body fees (industry-cited ranges, not a Venitara quote).

The common mistake

Classifying against an idealised future roadmap version of the product, rather than what's actually launching, is one of the most common ways founders get this wrong — usually discovering the correction only once it's quietly obsoleted a fundraising timeline. Worth tracking too: a live, not-yet-adopted European Commission proposal would revise the software-specific rule behind Class I/IIa outcomes — see What is MDR Rule 11, and why does it make my software Class IIa? for the current status.

Where next: MDR Annex VIII: How Device Classes Are Set · Do I need a Notified Body?

Find out in minutes where your product likely sits. Start the MedTech Compass → — AI-generated first read, not a validated determination.